0001127602-21-028169.txt : 20211102 0001127602-21-028169.hdr.sgml : 20211102 20211102181610 ACCESSION NUMBER: 0001127602-21-028169 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211030 FILED AS OF DATE: 20211102 DATE AS OF CHANGE: 20211102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Clyburn Frank CENTRAL INDEX KEY: 0001763963 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 211372868 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2021-10-30 0000310158 Merck & Co., Inc. MRK 0001763963 Clyburn Frank MERCK & CO., INC. 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 1 EVP & Pres ? Human Health Common Stock 2021-10-30 4 M 0 2358 88.05 A 98257.087 D Common Stock 2021-10-30 4 F 0 1162 88.05 D 97095.087 D Common Stock 2021-11-01 4 M 0 19915 0 A 117010.087 D Common Stock 2021-11-01 4 M 0 19847 0 A 136857.087 D Common Stock 2021-11-01 4 S 0 39762 87.8698 D 97095.087 D Common Stock - 401(k) Plan 1779.9447 I By 401(k) Restricted Stock Unit 2021-10-30 4 M 0 2358 0 D 2019-10-30 2021-10-30 Common Stock 2358 0 D Stock Option (Right to Buy) 43.65 2021-11-01 4 M 0 19915 0 D 2014-05-06 2023-05-05 Common Stock 19915 0 D Stock Option (Right to Buy) 56.49 2021-11-01 4 M 0 19847 0 D 2015-05-02 2024-05-01 Common Stock 19847 19848 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.8000 to $87.8950, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Holdings include shares acquired in dividend reinvestment transactions. Includes shares acquired and dividends earned through October 30, 2021 in the Merck U.S. Savings Plan, a 401(k) plan. Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. The restricted stock units vested and were distributed in equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016. The option became exercisable in equal installments on 5/2/2015, 5/2/2016, and 5/2/2017. /s/ Kelly E. W. Grez as Attorney-in-Fact for Frank Clyburn 2021-11-02